Compass Pathways' Q2 loss widens on commercial readiness activity costs

COMPASS Pathways

05/08/2026 11:45

Overview
UK mental health biotech's Q2 operating income missed analyst estimates
Net loss widened yr/yr, mainly due to non-cash warrant fair value adjustments
Company ended Q2 with $433 mln cash, expected to fund operations into 2028

Outlook
COMPASS Pathways expects to complete final NDA submission for COMP360 in Q4 2026
Company anticipates commercial launch of COMP360 in first half of 2027, pending approvals
Current cash position expected to fund operations into 2028

Result Drivers
R&D EXPENSES - Lower research and development costs as Phase 3 program for COMP360 in TRD nears completion and discovery program spending falls
COMMERCIAL PREPAREDNESS - Higher general and administrative costs to support commercial readiness activities
WARRANT FAIR VALUE ADJUSTMENTS - Widened net loss mainly due to non-cash fair value adjustments related to warrants, which fluctuate with share price

Company press release: ID:nBw9T0nhMa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.88
 
Q2 Net Loss
 
$253.79 mln
 
Q2 Operating Income
Miss
-$52.37 mln
-$47.06 mln (13 Analysts)
Q2 Operating Expenses
 
$52.37 mln
 
Q2 Pretax Loss
 
$253.46 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Compass Pathways PLC is $20.00, about 69.5% above its August 4 closing price of $11.80

Reuters Recommended Reads
Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Aug 4 - Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook
Aug 3 - AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)